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DNA ligase IV binds to XRCC4 via a motif located between rather
than within its BRCT domains
Ulf Grawunder, David Zimmer and Michael R. Lieber
The covalent rejoining of DNA ends at single-stranded
or double-stranded DNA breaks is catalyzed by DNA
ligases. Four DNA ligase activities (I—IV) have been
identified in mammalian cells [1]. It has recently been
demonstrated that DNA ligase IV interacts with and is
catalytically stimulated by the XRCC4 protein [2,3],
which is essential for DNA double-strand break repair
and the genomic rearrangement process of V(D)J
recombination [4]. Together with the finding that the
yeast DNA ligase IV homologue is essential for non-
homologous DNA end joining [5–7], this has led to the
hypothesis that mammalian DNA ligase IV catalyzes
ligation steps in both of these processes [8]. DNA
ligase IV is characterized by a unique carboxy-terminal
tail comprising two BRCT (BRCA1 carboxyl terminus)
domains. BRCT domains were initially identified in the
breast cancer susceptibility protein BRCA1 [9], but are
also found in other DNA repair proteins [10]. It has
been suggested that DNA ligase IV associates with
XRCC4 via its tandem BRCT domains and that this may
be a general model for protein—protein interactions
between DNA repair proteins [3]. We have performed a
detailed deletional analysis of DNA ligase IV to define
its XRCC4-binding domain and to characterize regions
essential for its catalytic activity. We find that a region
in the carboxy-terminal tail of DNA ligase IV located
between rather than within BRCT domains is
necessary and sufficient to confer binding to XRCC4.
The catalytic activity of DNA ligase IV is affected by
mutations within the first two-thirds of the protein
including a 67 amino-acid amino-terminal region that
was previously thought not to be present in human
DNA ligase IV [11].
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Results and discussion
The basis for the deletional analysis of DNA ligase IV was
a PCR clone containing an open reading frame (ORF)
from position 274 to 3007 of the published cDNA
sequence [11] that was amplified from REH pre-B-cell
cDNA. This ORF encodes recombinant DNA ligase IV
that is 67 amino acids longer at the amino terminus than
the proposed human DNA ligase IV protein [11]. There
are two reasons for choosing the longer ORF as a basis for
our deletional mutagenesis. First, two independent DNA
ligase IV expression vectors containing the shorter ORF
expressed inactive DNA ligase IV, whereas several clones
encoding the longer ORF yielded DNA ligase IV that was
readily active in nick ligation assays (data not shown).
Second, alignment of the human and yeast DNA ligase IV
protein sequences demonstrated significant homology
upstream of the putative start methionine of human DNA
ligase IV (Figure 1). In fact, the start methionine that was
suggested as the first amino acid of human DNA ligase IV
is not conserved in yeast (Figure 1). Throughout this
study we therefore consider the 911 amino-acid version of
DNA ligase IV as the wild-type protein. 
In order to broadly define functional regions within DNA
ligase IV, several deletions covering the entire length of
the protein were initially generated as shown in Figure 2a.
Deletion mutants L4∆1 and L4∆2 recreated the ‘short’
version of DNA ligase IV expressed from the putative
ATG start codon 475 as suggested by Wei et al. [11]. The
mutants differed by their translational initiation sequences
(L4∆1 containing the endogenous one and L4∆2 contain-
ing a perfect Kozak consensus sequence). Although both
Figure 1
Sequence alignment of the amino-terminal 120 amino acids of human
DNA ligase IV (hLigIV) and Saccharomyces cerevisiae DNA ligase IV
(yLigIV). Identical amino acids are boxed and homologous amino acids
are shaded. The location of the putative start methionine of human DNA
ligase IV as suggested by Wei et al. [11] is indicated by a black dot.
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L4∆1 and L4∆2 mutants were equally well expressed,
they were inactive in nick ligation assays (see Supplemen-
tary material). Altogether a total of four independent
clones encoding the short form of DNA ligase IV were cat-
alytically inactive. This makes it highly unlikely
(p = 0.064 = 1.3 × 10–5, see Materials and methods) that
PCR errors are responsible for this result. We therefore
suggest that fully active human DNA ligase IV requires an
additional 67 amino-terminal amino acids to the protein
originally proposed [11]. 
DNA ligase IV deletion mutants L4∆3, L4∆4, L4∆5 and
L4∆6 were designed to contain 200 amino-acid deletions
throughout the entire protein sequence, whereas mutants
L4∆7 and L4∆8 had the carboxy-terminal 111 amino acids
deleted (Figure 2a; L4∆7 and L4∆8 were derived by dif-
ferent cloning strategies). All DNA ligase IV deletion
mutants were found to be expressed at comparable levels
and could be immunoprecipitated and detected with a
monoclonal antibody against their hemagglutinin (HA)
epitope tags (Figure 2b).
Interaction of the various DNA ligase IV mutants with
XRCC4 was tested by co-immunoprecipitation with
human XRCC4 tagged with the Myc epitope. All DNA
ligase IV deletion mutants except mutant L4∆6 were able
to efficiently co-immunoprecipitate with XRCC4
(Figure 2c). This indicates that a region between amino
acids 600 to 800 of DNA ligase IV is essential for XRCC4
binding. Notably, deletion mutants L4∆7 or L4∆8 carry-
ing a deletion of the entire BRCT II domain were not
compromised for XRCC4 binding. Analysis of the catalytic
activities of mutants L4∆1 to L4∆8 indicated that only the
carboxy-terminal 111 amino acids were dispensable (see
Supplementary material). 
Having identified a 200 amino-acid stretch within the
carboxy-terminal tail of DNA ligase IV that is essential for
XRCC4 binding, we proceeded to generate further
50-amino-acid deletions within this region (Figure 3a). All
deletion mutants were found to be expressed (Figure 3b),
and co-immunoprecipitation studies showed that only
deletion mutant L4∆12 failed to associate with XRCC4
(Figure 3b,c). This mutant contains a deletion of the
region located between the two BRCT domains. We
therefore conclude that this region, rather than the BRCT
domains themselves, is required for XRCC4 binding.
Whereas wild-type catalytic activity was retained in dele-
tion mutants L4∆10, L4∆11 and L4∆12, we did not detect
significant nick ligation activity for deletion mutant L4∆9
(see Supplementary material), for which two independent
clones were tested. This deletion is nearest to the pro-
posed catalytic core of DNA ligase IV and it is therefore
possible that the deletion either has a structural effect on
the catalytic core or that the catalytic domain extends
slightly past the first 600 amino acids into the deletion
zone of L4∆9. 
The finding that the inter-BRCT region of DNA ligase IV
is essential for XRCC4 binding does not rule out the possi-
bility that either of the BRCT domains alone might be able
to interact with XRCC4 or that the region from amino acids
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Figure 2
(a) Graphic representation of a set of DNA ligase IV deletions. The
deleted regions of each mutant are shown below the diagram of DNA
ligase IV. Deletion mutants L4∆1and L4∆2 carry deletions of the first
67 amino acids of DNA ligase IV expressed from ORF 274–3007,
recreating the shorter version of the molecule that was originally
proposed to be full-length DNA ligase IV [11]. The unique carboxyl
terminus begins at amino acid 605. The originally proposed start
methionine (M68) [11], as well as the active site of DNA ligase IV
(amino acids 273–278) including the reactive lysine residue K273 are
indicated. H6 indicates six copies of the His tag and HA indicates the
hemagglutinin tag. (b,c) Co-immunoprecipitation studies with DNA
ligase IV deletion mutants and XRCC4. HA-tagged human DNA ligase
IV mutants were transiently co-expressed with Myc-tagged human
XRCC4 as indicated and cell lysates were prepared. Controls included
full-length DNA ligase IV (wt) and XRCC4 expressed individually and in
combination. (b) Proteins immunoprecipitated (IP) with an anti-HA
antibody were eluted from immunobeads with HA peptide and western
blotted with anti-Myc and anti-HA antibodies. An HA cross-reactive
protein at ~80 kDa was detected in all anti-HA immunoprecipitations
and is partly masking the signal for deletion mutants L4∆5 and L4∆6.
Redundant deletion mutants L4∆2 and L4∆7 are not shown, as they
behaved identically to deletion mutants L4∆1 and L4∆8, respectively.
Signals detectable below the 80 kDa background band on the blot are
derived from XRCC4 protein. (c) Proteins from the same lysates as in
(b) were immunoprecipitated with an anti-Myc antibody and subjected
to western blotting with anti-Myc and anti-HA antibodies. XRCC4-
derived signals are detectable between 60 and 65 kDa. Heavy (H) and
light (L) chains of the anti-Myc monoclonal antibody are indicated.
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751 to 800 might be required to bring the BRCT domains
into the correct structural context for XRCC4 binding. We
therefore created a DNA ligase IV deletion mutant that
lacked both BRCT domains (Figure 4a). Co-immunopre-
cipitation studies with this mutant demonstrated that even
in the complete absence of both BRCT domains DNA
ligase IV was able to efficiently bind XRCC4 (Figure 4c).
Therefore the inter-BRCT region of DNA ligase IV is nec-
essary and sufficient for XRCC4 binding.
In a set of six smaller deletions and mutations within the
XRCC4-interacting region (XIR), we found that only
deletion of amino acids 767–783 (IDTDLNQLKEVFS-
GIKN) within the XIR entirely disrupted XRCC4 binding
(see Supplementary material). This region shows very
little conservation between the human and yeast DNA
ligase IV homologues, indicating that a structural yeast
homologue of mammalian XRCC4 might not exist. Func-
tional divergence between the human and yeast DNA
ligase IV proteins is also suggested because human DNA
ligase IV failed to complement the DNA repair defect in
yeast deficient in DNA ligase IV (T.E. Wilson, U.G. and
M.R.L., unpublished observations). 
Our study represents the first detailed deletional analysis
of a protein, DNA ligase IV, containing BRCT domains,
and we find no evidence that these domains are involved
in conferring binding to XRCC4. The region in the
carboxy-terminal tail of DNA ligase IV that is critical for
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Figure 3
(a) Schematic representation of the 50-amino-acid deletion mutants
within the unique carboxy-terminal tail of DNA ligase IV. The deleted
regions of each mutant are shown. The location of the BRCT I and
BRCT II domains are indicated by blue boxes. (b,c) Co-
immunoprecipitation studies with the deletion mutants L4∆9–12. An
identical set of experiments with the same controls was performed as
described for Figure 2b,c. Controls were the same as depicted in
Figure 2b.
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Figure 4
(a) Generation of deletion mutant L4∆19 that lacks both BRCT
domains. Schematic representation of the unique carboxy-terminal tail
(amino acids 600–911) of wild-type DNA ligase IV (left) including
BRCT domains I and II and the region required for XRCC4 binding
(XIR, for XRCC4-interacting region). Mutant L4∆19 was generated
from L4∆8, which already lacked the BRCT II domain, by internally
deleting the BRCT I domain. The carboxy-terminal tail of L4∆19 (right)
therefore contained only the 50-amino-acid XIR (751–800) fused to
the amino-terminal 657 amino acids of DNA ligase IV. (b,c) Co-
immunoprecipitation studies with L4∆19. Two independent clones of
L4∆19 (∆19-1 and ∆19-2) were expressed in XR-1 CHO cells with or
without XRCC4. Full-length DNA ligase IV (wt) was used as a positive
control and deletion mutant L4∆12 lacking the XIR (see Figure 3) as a
negative control. XRCC4 expressed alone or untransfected cells (as
indicated) served as additional negative controls. (b) An anti-HA
immunoprecipitation (IP) was subjected to western blotting with anti-
HA antibodies to demonstrate expression of all DNA ligase IV
expression constructs. L4∆19 migrates slightly below an ~80 kDa
background band detected by the anti-HA antibody. (c) An anti-Myc
immunoprecipitation was subjected to western blotting with anti-HA
and anti-Myc antibodies to visualize the Myc-tagged XRCC4 as well as
the HA-tagged DNA ligase IV proteins.
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the interaction with XRCC4 is located in-between rather
than within the BRCT domains suggesting a different
role of these domains for the function of DNA ligase IV.
Tandem BRCT domains were first defined in the
carboxy-terminal portion of BRCA1 [9]. BRCA1 binds to
the homologous DNA repair factor Rad51, but the inter-
action occurs via a separate interaction domain located in
the center of the protein [12]. The only case where
protein–protein binding might be conferred by BRCT
domains is in the case of the XRCC1–DNA ligase III
association [13], where the interacting regions have been
mapped very closely to the BRCT domains [14]. Because
BRCT domains are found in many proteins involved in
DNA repair and cell cycle regulation, it will be of
considerable interest to determine the main function of
BRCT domains, and whether they can influence
protein–protein interactions.
Materials and methods
Generation of DNA ligase IV deletion mutants
DNA ligase IV deletion mutants were generated by PCR from expres-
sion construct pUG22 containing the DNA ligase IV ORF 274–3007
cloned into pCDNA3 as an HA-tagged version. All PCRs were carried
out with KlenTaq DNA polymerase, which has a reduced error rate
[15]. Using KlenTaq enzyme the probability per cycle for a point muta-
tion for a 3 kb template is p = 0.03. The probability of a single PCR
clone after i PCR cycles is therefore given by:
For many PCR cycles (that is, where i = 40) the probability can be
approximated to p = 0.06. Amino-terminal deletions were generated
using an internal DNA ligase IV primer and a universal downstream
primer binding in the vector backbone. Internal deletion mutants were
generated by a two-step PCR approach (see Supplementary mater-
ial): fusing an amino-terminal piece of the DNA ligase IV cDNA to a
carboxy-terminal piece. Deletion mutant L4∆19 carrying a deletion of
both BRCT domains was generated by internally deleting the BRCT I
domain from deletion mutant L4∆8 that already lacked a BRCT II
domain. Individual deletion mutant clones were tested by combina-
tions of 3–4 diagnostic restriction enzyme digests, and in some cases
by DNA sequencing. 
Transient expression of proteins, immunoprecipitations and
western blotting
For all co-immunoprecipitation studies, proteins were transiently
expressed in XR-1 CHO cells using the vaccinia virus overexpression
system [16]. In cases where constructs were tested for expression,
HeLa cells were used instead. Immunoprecipitations of epitope-tagged
proteins were performed as described [2]. HA-tagged proteins were
occasionally eluted from the immunobeads with 200 mM HA peptide
for 16 h at 4°C in order to reduce antibody-derived background
signals. Enhanced chemiluminescent western blotting with either puri-
fied anti-HA monoclonal antibody 12CA5 or anti-Myc monoclonal anti-
body 1-9E10.2 was performed as described [17].
In vitro ligation assays
In vitro ligation assays were performed in 60 mM Tris-Cl, 10 mM
MgCl2, 5 mM DTT and 5 µg/ml acetylated BSA, pH 7.9. Ligations were
performed with 0.1 pmol of a 32P-labeled nick ligation substrate for
30 min at 37°C, denatured at 95°C in formamide and fractionated by
20% denaturing PAGE. 
Supplementary material
Two figures showing analysis of the XIR of DNA ligase IV and details of
the PCR mutagenesis, a table showing the nick ligation activities of the
mutants, and the PCR primer sequences are published with this paper
on the internet.
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Materials and methods
PCR primer sequences for the generation of DNA ligase IV
mutants
Universal upstream primer (with BamHI cloning site): 5′-CGGGATC-
CATGGCTGCCTCACAAACTTCACAAACTG-3′. Universal downstream
primer (with XbaI cloning site): 5′-GCCCTCTAGATGCATGCTC-
GAGCGG-3′. Alternative downstream primer for cloning of L4∆8 (with
AvrII cloning site): 5′-AAAGCCTAGGCCTCCAAAAAAGCCTCC-3′.
Upstream primers for amino-terminal deletion mutants: L4∆1
(∆aa1–67) 5′-TTATGGATCCATGAGACTAATTCTTCCTCAG-3′.
L4∆2 (∆aa1–67, with Kozak sequence): 5′-CTCTGGATCCATG-
GCAATGAGACTAATTCTTCCTGAG-3′), L4∆3 (∆aa1–196),
5′-CCATGGATCCATGGTTAGTCAGCAAACTATCTTTTC-3′. 
Internal primers for deletion mutants
L4∆4 (∆aa200–400): amino-terminal primer: 5′-GTTTTCTGCACTATTTC-
CTGACTAACACCAAGCTTTAAATCCTTTATG-3′, carboxy-terminal
primer: 5′-AGCTTGGTGTTAGTCAGGAAATAGTGCAGAAAACA-
CAAGCTCATACT-3′.
L4∆5 (∆aa381–600): amino-terminal primer: 5′-GCCTTCCCCCTAA-
GTTGCTCATGCCCTAGCTTTTTATTATTAACCATC-3′, carboxy-terminal
primer: 5′-AAAAGCTAGGGCATGAGCAACTTAGGGGGAAG-
GCATCTGGTAAGCTC-3′.
L4∆6 (∆aa601–800): amino-terminal primer: 5′-TCCCAGGAATACC-
GATATTCTAGGTCGTCCAGGGTCATGCACTCATG-3′, carboxy-terminal
p r i m e r : 5 ′ - C C C T G G A C G A C C T A G A A T A T C G G T A T T C -
CTGGGATTGCTCTCCTCTC-3′.
L4∆7 (∆aa801–910): amino-terminal primer: 5′-TGGTGATGGTGAT-
GGTGTTCTAAATCAGCAATCAGAGAAGCCATTTC-3′, carboxy-terminal
primer: 5′-TGATTGCTGATTTAGAACACCATCACCATCAACATCAC-
CATCACGCGTTGGCTTAC-3′.
L4∆9 (∆aa601–650): amino-terminal primer: 5′-ATTAGAAATTTTGT-
TAACGTTTTCTAGGTCGTCCAGGGTCATGCACTCATG-3′,
carboxy-terminal primer: 5′-GACCCTGGACGACCTAGAAAACGT-
TAACAAAATTTCTAATATATTTGAAG-3′.
L4∆10 (aa∆651–700): amino-terminal primer: 5′-GTTCTCAGACCCTG-
CAATAGTAAGGTTAGGTGCTTTTAAGTGCTCAAT-3′, carboxy-terminal
primer: 5′-AAAGCACC TAACCTTACTATTGCAGGGTCTGAGAACAT-
CAGAGTGAAA-3′.
L4∆11 (aa∆701–750): amino-terminal primer: 5′-ACGGGCAAAAT-
GTTCTTTTACACAGTACGTGTCTGGGCCTGGATTTTG-3′, 
carboxy-terminal primer: 5′-CCAGACACGTACTGTGTAAAAGAA-
CATTTTGCCCGTGAATATGATTGC-3′.
L4∆12 (aa∆751–800): amino-terminal primer: 5′-ATCCCAGGAATACC-
GATAGGTTGATGGGCACATATGAATCATAAAGCG-3′, carboxy-terminal
primer: 5′-CATATGTGCCCATCAACCTATCGGTATTCCTGGGATTG-
CTCTCCTCTC-3′.
L4∆13 (aa∆751–766): amino-terminal primer: 5′-GTTCAAGTCTGTAT-
CAATGGTTGATGGGCACATATGAATCATAAAG-3′, carboxy-terminal
primer: 5′-CATATGTGCCCATCAACCATTGATACAGACTTGAAC-
CAACTGAAG-3′.
L4∆14 (aa∆767–782): amino-terminal primer: 5′-AGGAGTCT-
GCTCGTTAGAGAAATAACTATCACCATAGCAATCATATTC-3′,
carboxy-terminal primer: 5′-TGCTATGGTGATAGTTATTTCTCTAAC-
GAGCAGACTCCTGAAGAAATG-3′.
L4∆15 (aa∆783–800): amino-terminal primer: 5′-ATCCCAGGAATAC-
CGATAATTTTTAATTCCTGAGAATACTTCCTTC-3′, carboxy-terminal
pr imer : 5 ′ -GTATTCTCAGGAATTAAAAATTATCGGTATTC-
CTGGGATTGCTCTCC-3′.
Primer sequences for two-amino-acid substitution mutants
L4M16 (759/60 DC→AS): amino-terminal primer: 5′-ACTATCAC-
CATAGCTAGCATATTCACGGGC-3′, carboxy-terminal primer: 5′-
GCCCGTGAATATGCTAGCTATGGTGATAGT-3′.
L4M17 (763/64 DS→GA): amino-terminal primer: 5′-ATCAAT-
GAAATAGGCGCCACCATAGCAATC-3′, carboxy-terminal primer: 5′-
GATTGCTATGGTGGCGCCTATTTCATTGAT-3′.
L4M18 (798/99 DL→GT): amino-terminal primer: 5′-ATACC-
GATATTCGGTACCAGCAATCAGAGA-3′, carboxy-terminal primer:
5′-TCTCTGATTGCTGGTACCGAATATCGGTAT-3′.
Primers for the deletion mutant lacking BRCT domains, L4∆19
(aa∆658–743 plus ∆801–911): amino-terminal primer: 5′-AACGTTAA-
CAAAATTTCTAATATTCATATGTGCCCATCAACCAAAGAAC-3′,
carboxy-terminal primer: 5′-GGTTGATGGGCACATATGAATATTA-
GAAATTTTGTTAACGTTAGTAAG-3′.
Supplementary material
Table S1
Activity of DNA ligase IV mutants in nick ligation assays.
Deletion Catalytic Deletion Catalytic
mutant activity* mutant activity
L4∆1 ND† L4∆10 wt
L4∆2 ND L4∆11 wt
L4∆3 ND L4∆12 wt
L4∆4 ND L4∆13 wt
L4∆5 ND L4∆14 wt
L4∆6 ND L4∆15 wt
L4∆7 wt L4M16 wt
L4∆8 wt L4M17 wt
L4∆9 ND‡ L4M18 wt
ND indicates no detectable activity (< 1% conversion of substrate). Wt
indicates wild-type activity. *Catalytic activities of DNA ligase IV
mutants relative to the wild-type protein varied from 50–150% upon
phosphorimager analysis and are therefore only qualitatively reported.
†Four independent clones tested. ‡Two independent clones tested.
S2 Supplementary material
Figure S1
(a) Sequence alignment of the XRCC4-
interacting region (XIR) in human DNA ligase
IV (hLigIV) with homologous sequences in
yeast DNA ligase IV (yLigIV). The XIR extends
from amino acids 751 to 800 located
between the two BRCT domains and is
indicated by a black bar on top of the human
sequence. Identical amino acids are boxed
and homologous amino acids are shaded.
Vertical separators within the horizontal bar
representing the XIR indicate the location of
three deletions that were generated (L4∆13,
L4∆14 and L4∆15). Asterisks represent the
position of two-amino-acid substitutions in
three other mutants (L4M16, L4M17 and
L4M18). Details of the mutants are given
below the alignment. (b,c) Co-
immunoprecipitation studies with the XIR
mutants. An identical set of experiments was
performed as described for Figure 2b,c.
Controls included wild-type DNA ligase IV and
XRCC4 protein in all possible combinations
(that is, co-expressed, individually expressed
and not expressed at all). Apparent molecular
weights of the XIR mutants were close to the
molecular weight of the full-length wild-type
protein, 110 kDa.
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Figure S2
Schematic overview of the PCR mutagenesis:
a two-step PCR approach for the generation
of internal deletion mutants. Two parallel
PCRs were performed with full-length DNA
ligase IV ORF as a template using universal
upstream and downstream cloning primers
(primer 1 and primer 2) in combination with
internal primers as depicted. The internal
primers were designed such that the internal
primer for amplification of an amino-terminal
fragment of the cDNA had a 18–21 nt 5′
overhang that was complementary to the
priming sequence of the internal primer used
for amplification of the carboxy-terminal
fragment. Likewise, the internal primer for the
carboxy-terminal PCR fragment carried a
18–21 nt 5′ overhang that was
complementary to the priming sequence of
the internal amino-terminal primer. The
resulting PCR fragments are therefore
identical at their internal ends allowing
annealing of DNA strands if the PCR products
are combined in a secondary PCR. A fusion
product between these PCR fragments is
then selectively amplified using the universal
upstream and downstream PCR primers. 
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